Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
November 6, 2024
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, and thanks for being with us on this call covering our business update and results for the third quarter of 2024. On the line with me are two colleagues: Lisa Delfini, who serves as Trevi's Chief Financial Officer, and Dr. James Cassella, our Chief Development Officer. I'll share news about our studies and the data milestones coming up, Lisa will follow with a quick financial summary, and afterward the three of us look forward to taking your questions. To begin, I'd like to spend a moment introducing Jim Cassella, who joined our leadership team as Chief Development Officer not long ago. Jim, as many of you are likely aware, served on our Board of Directors for the past 4 years, and throughout that period he gave me guidance of enormous value. His expertise in developing neuroscience drugs is extensive — over 35 years have been dedicated to CNS therapies. Prior to joining Trevi, Jim served as CDO at Concert Pharmaceuticals, which Sun Pharma acquired in 2023, and in that role he supervised development efforts that resulted in successful U.S. FDA approval for Leqselvi, an autoimmune JAK inhibitor. Earlier in his career, between 2004 and 2015, Jim worked at Alexza Pharmaceuticals as EVP, Research and Development and CSO, where he led the effort to secure U.S. and European approval for Adasuve, a CNS drug. Jim holds a doctorate in Physiological Psychology from Dartmouth College, and he completed postdoctoral training in Yale School of Medicine's Department of Psychiatry. He brings extensive development know-how to Trevi, including experience with Phase 3 and a recent regulatory approval, and that will be extremely valuable as we advance into late-stage development. He joins Trevi at a thrilling time, as key studies report results over the next several months and as we prepare for pivotal Phase 3 trials and an NDA submission. So, Jim, welcome aboard. Trevi had a very busy quarter. We continue to carry out our clinical development strategies for people who have chronic cough and idiopathic pulmonary fibrosis, which we call IPF, as well as for patients suffering from refractory chronic cough, known as RCC. There are multiple data readouts coming up, and our goal is to extend the solid efficacy we saw in our Phase 2a study that enrolled IPF chronic cough patients. With both of our programs advancing further into clinical development, rival companies' offerings have continued to disappoint, in IPF disease modification studies and in medications being tested for RCC, which is a reminder that patients facing these severe conditions still desperately require new treatment options. Next, I want to give you an update on the upcoming clinical data readouts, which I see as key drivers of value for the company. I'll go through them in the sequence we expect them to occur. The Human Abuse Potential study, or HAP, comes first. I've discussed this with investors and analysts so many times that I'm sure all of you now feel you know more about HAP studies than you ever cared to; so let me review the key points on HAP as we prepare for the data. As a reminder, injectable nalbuphine, which is approved for severe pain, has been on the market for decades and the DEA has kept it unscheduled. On a routine basis, the DEA evaluates how molecules should be scheduled, and its decisions rest on the chemical entity itself rather than on how a drug gets delivered. Their most recent review took place in 2023, and as of that point they had left nalbuphine off the scheduled list. I think it's worth walking you through the reasoning they laid out in that recent opinion. The first point concerns nalbuphine's distinctive way of working in the body. It acts as a kappa agonist while blocking mu, making it a KAMA, and that places it among the mixed agonist-antagonist compounds. Every drug falling into either the kappa agonist or mu antagonist category remains unscheduled, and such agents were created specifically to reduce the likelihood of misuse. The second point is that nalbuphine holds less appeal for people who abuse substances, because it strongly blocks mu receptors and thereby triggers withdrawal symptoms. Third, nalbuphine is already on the market. Even so, the DEA points out that law enforcement rarely runs into it, and forensic labs seldom receive it for testing. That means the molecule has a long track record and is nothing new to the DEA. Given that, what's the reason for running the HAP study? Back in 2017, the FDA issued guidance calling for HAP studies on every CNS active drug, so our aim is to update the package to meet today's standards. Last, the Controlled Substance Staff, or CSS, which is a group within the FDA, will review this study as part of the Eight Factor plan. When it comes to the Eight Factor plan, there are multiple categories, and the HAP is just one of them. So the final data still needs to come in, but we think there are plenty of grounds to expect that nalbuphine, if it gets approved for chronic cough, will stay unscheduled. All right, let's turn to our clinical indications. The next set of data we expect is the sample size re-estimation from our IPF cough trial. Before that, I'd like to point out that IPF patients have had few new treatment choices since the antifibrotics came on the market 10 years ago, and among the two approved antifibrotics, neither has demonstrated a meaningful decrease in chronic cough. Next, apart from the results from our Phase 2 study, no trials focused on IPF cough have succeeded, even though coughing ranks among the main issues these individuals report. Also, our view is that coughing could act as a risk factor contributing to how the disease itself advances. Ongoing damage to the lungs, small tears, and possible inflammation brought on by continuous coughing might produce poorer health results for patients, including more hospital stays related to breathing, death, or the requirement for a transplant. Therefore, we remain convinced that this program matters greatly to these patients, the people close to them, and their physicians. The CORAL study, our Phase 2b trial in IPF chronic cough, uses a parallel-arm, dose-ranging design and will look at placebo plus three active Haduvio doses. Around 160 patients will take part in this six-week trial. For CORAL, the upcoming milestone involves running the sample size re-estimation, or SSRE, analysis once 50% of participants have finished the study. An unblinded statistician from outside the company will handle this analysis, rerunning the power calculations with actual data. The information we receive back will be quite limited, but we will learn which of three possible outcomes applies. First, proceed with the planned 160 patients, which would reconfirm the original powering assumptions. Second, the drug is landing inside the promising zone we defined in advance, though we'll need to increase enrollment to preserve statistical power. Third, the drug is falling outside the pre-specified range, in which case the company ought to weigh halting the trial or declaring futility. After we obtain these findings, we will disclose the analysis results, and our expectation is that this happens in December of this year. If the SSRE outcome permits it, our expectation for top line data from the full study remains the first half of 2025. As I see it, provided the answer we get back isn't futility, the SSRE acts as a major de-risking milestone for the trial's eventual success. In this study, the statistical range's upper bound and the original N both line up with a placebo-adjusted change that carries clinical significance.
Jennifer Good
executiveTherefore, the main issue revolves around figuring out the right number of participants for this group being studied. Following the SSRE and the IPF cough, we expect to have results in Q1 of 2025 from our RIVER trial, which is phase 2a, focused on RCC. This illness, RCC, is terrible and affects about 2 million to 3 million grown-ups in America, and it involves a cough lasting over eight weeks, persisting even when a root cause is treated, or when there's no root cause at all. Because no treatments are approved for RCC in the U.S., and many potential drugs have flopped, there's a big need that isn't being met, and both patients and doctors are eager for fresh approaches. Although there have been plenty of setbacks in creating RCC therapies, we believe our unique approach—acting both centrally and peripherally—could change the outcome. Every one of those unsuccessful medications worked only on the peripheral side. The forms of cough we're studying involve hypersensitivity within the brain, and that's the reason we think our mechanism may prove relevant here. For our RCC study, we're using a Phase 2a crossover format, something that's been employed in lots of industry cough studies, and it was intended to bring in roughly 60 participants. Those enrolled were assigned by randomization to receive either nalbuphine or a placebo, and they were stratified according to cough count. A moderate cough level means somewhere between 10 and 19 coughs each hour, while anything at 20 or more coughs per hour counts as high. Our main analysis is going to cover the entire population, yet we'll still be able to see if the drug shows an effect specifically in moderate coughers — a group where competing programs haven't succeeded. Enrollment for this trial is complete, and the final patient's last visit happens in early 2025. We look forward to wrapping up the study and sharing results for this important chronic cough condition during the first quarter of 2025. So, as you can see, we've come quite a long way in recent months when it comes to finishing enrollment and dosing, and we're really looking forward to seeing what the data shows for each of these trials. In summary, HAP data should arrive in December of this year, and the CORAL Phase 2b SSRE is expected by year end as well. Moving into 2025, we anticipate RIVER Phase 2a top line data during Q1 2025, and then top line results from the complete CORAL Phase 2b study in the first half of 2025, provided the sample size doesn't grow. This is an exciting period for Trevi, with a strong flow of news over the coming months, all of which represent significant value inflection points. Lisa will now take over to walk us through the financials.
Lisa Delfini
executiveThanks, Jennifer, and hello everybody this afternoon. You can find the complete financial results for the 3 months that ended September 30, 2024 in the press release we put out before this call, as well as in our 10-Q, which we filed with the SEC today after the market closed. During the third quarter of 2024, our net loss came in at $13.2 million, versus a net loss of $7.7 million in the same quarter of 2023. R&D expenses reached $11.2 million in the third quarter of 2024, compared with $6.3 million in the comparable quarter of 2023. This higher R&D spend is a reflection of the substantial clinical development work Jennifer just walked through, such as ongoing enrollment in our CORAL trial in chronic cough and IPF, the last complete quarter of enrollment in the RIVER trial in RCC, and the last complete quarter of dosing in the HAP trial. G&A expenses came to $2.9 million in the third quarter of 2024, versus $2.7 million in the same period of 2023, mostly because of a rise in stock-based compensation expense, and notably this shows our discipline over overhead costs, something we remain attentive to. As of September 30, 2024, cash, cash equivalents and marketable securities came to $65.5 million, compared with $83 million as of December 31, 2023. We currently expect our 2024 cash burn, excluding proceeds from share issuances and interest and investment income, to land between $41 million and $43 million, consistent with what we guided previously; we now anticipate cash runway into the second half of 2026, which is more than a year beyond all currently projected data readouts. That wraps up our prepared remarks. I'll hand the call back to the operator now for Q&A.
Faisal Khurshid
analystHi all, thanks for taking my question. I also wanted to extend a welcome to Jim and congratulations regarding the new hire. So, for the…
James Cassella
executiveThank you very much.
Faisal Khurshid
analystYeah, and regarding the half, could you make clear what you're anticipating for butorphanol drug liking, and what evidence backs that up? And I completely get your point that scheduling looks at the whole eight factor analysis; but for nalbuphine in the HAP, what would you need to see to back an unscheduled designation rather than a possible Schedule IV?
Jennifer Good
executiveThanks, Faisal. I'll have Jim take that one.
James Cassella
executiveAbsolutely, thank you — it’s a pleasure to be here and great to meet you. These trials are complex, and the people conducting them are experts working with subjects who’ve had prior exposure to the drug. Butorphanol is a scheduled medication, and it has a history of being abused by participants. Because of that, we don’t assume anything — anyone who wants to take part has to meet qualification criteria during a butorphanol qualification phase. In other words, we impose entry requirements, meaning they must hit specific thresholds in absolute terms and also show a distinction from placebo. That way, we can be confident that butorphanol will produce measurable effects in the trial, and this portion of the design has already received FDA approval. So when we examine this trial — and consider it within the broader context of scheduling — ultimately, it’s built to address several things. The main endpoint is the VAS drug liking scale. Our goal there is to establish that the study is valid by demonstrating that butorphanol separates from placebo, and there’s a predetermined threshold of no less than 15 points for that. We’ll also assess relative abuse liability by comparing nalbuphine with butorphanol, which will let us see whether nalbuphine has lower relative abuse potential based on pre-specified statistical endpoints that the FDA reviewed and approved. And just as importantly, we’ll evaluate nalbuphine’s absolute abuse potential relative to placebo. In that instance, we can determine — using a preset equivalence margin of 11 points within the placebo arm, also reviewed and approved by the FDA — whether each dose falls significantly inside that 11-point range from placebo. If it does, we can state that no abuse-related signal appears compared with placebo. Those are the three outcomes tied to the primary efficacy endpoint of drug liking. From there, we’ll move forward by considering additional evidence from the study’s other endpoints and situating it within the full package we’ll need to present to the FDA — including things such as findings from our other clinical trials and the other items Jennifer mentioned from the latest DSS <<inaudible>> analysis of nalbuphine.
Faisal Khurshid
analystUnderstood. That helps a lot. Thanks.
Leland Gershell
analystHi, thanks for the update, and I'd also like to welcome Jim. Thanks for taking the questions. I'll attempt to stick to one, though it may have several parts. Jen, I just wanted to ask, regarding the SSRE, if that turns out to be the result, would there be a set bump in sample size that gets triggered? Or would it vary based on how many additional patients you might need to add prospectively, given what has been observed, and if it is fixed, have you disclosed what that number would be? Thank you.
Jennifer Good
executiveYes. No, that's a good question, Leland. Thank you; so essentially, the range we pre-specified for the SSRE is the original N of 160 and it can go up to a total N of 400. It is not a fixed increase; they're going to take the actual number seen through 50%, repower the study and give us an exact number. So it can be anywhere in that range between 160 and 400 that they would come back with.
James Cassella
executiveOne more thing to add on that: we'll be examining the conditional probability behind what we found, and after that we can scale up accordingly. Once again, that will operate on a sliding scale tied to whatever conditional probability the SSRE ends up determining.
Leland Gershell
analystI appreciate it. I'll get back in line.
Jennifer Good
executiveThank you, Leland.
Deb Chatterjee
analystHello, and thank you for allowing me to ask. I may have overlooked this, so would you mind verifying that within the RCC trial the pair of arms — that is, those with differing levels of coughing — are at this point even?
Jennifer Good
executiveDebanjana, I appreciate the question. What she is inquiring about is whether, now that enrollment has been completed, both of those arms in the RCC trial are balanced.
James Cassella
executiveYes. Balanced in terms of the treatment assignment?
Jennifer Good
executiveI think she's talking about the stratification, one to one.
James Cassella
executiveRegarding the stratification — absolutely. What we aimed for was to make the trial available to individuals grouped by a cough count falling between 10 and 19, or exceeding 20. To bring in additional participants for the moderate arm, we extended how long enrollment stayed open. At some stage, we made the call to halt it rather than hold out for full balance. That is, balance across all enrolled participants with respect to that stratification factor. The overall analysis isn't really affected by this, since it relies on how many people are in the trial, not on those subgroup analyses. So that's not something we're worried about in the least; and my sense is there will be enough people in that group for us to conduct forward-looking statistical work and planning for our larger — the Phase 2b or Phase 3 program. Still, I believe we'll have adequate numbers there, which is the reason we chose to stop at the point we did.
Deb Chatterjee
analystOkay. Thanks for the color.
James Cassella
executiveSure.
Jennifer Good
executiveThanks, Debanjana and we're looking forward to your call.
William Wood
analystHello. William Wood here, filling in for Mayank today. Thanks for letting us ask questions, and congratulations on the solid quarter; so, just to pick up where we left off regarding the HAP trial. I'm just somewhat interested in what would take place once you get the trial's findings, perhaps the following actions. Would you — basically would you head straight to the FDA with those findings? Or would this kind of get folded into a bigger midyear 2025 end of Phase 2 meeting?
Jennifer Good
executiveI'll take that first, William and Jim is clearly only now joining us. So he might offer some differing perspectives. But we'll clearly obtain the data. We'll eventually file the CSR and the results concerning that. We'll, without a doubt, talk about it during our end of Phase 2 meeting on the IPF trial and likely ask for any feedback back. But I would picture that we'll fold that into our subsequent FDA meeting; but we'll file the results in advance. Jim anything?
James Cassella
executiveSure. So, for medications of this kind, this is a typical sort of study. We'll send the CSR along with all the data over to the FDA according to the normal schedule. Also, when it comes to examining upcoming efficacy trials in our indications, this study isn't really a gate for us; so it would be more a question of the NDA rather than the actual process of running our clinical programs.
William Wood
analystAll right, just to confirm, it wouldn't have any impact on the trials that are currently ongoing either?
James Cassella
executiveCorrect.
Jennifer Good
executiveNo.
James Cassella
executiveNo. And once more, this represents just one among numerous data points that the DEA actually takes into consideration. I believe we simply hope that everybody keeps in mind that nalbuphine has existed for decades and remains unscheduled. As Jennifer mentioned, it's the moiety that typically gets evaluated. That gets evaluated when it comes to scheduling. So this is a distinct formulation. We're working to bring half data into nalbuphine's domain. So once more, every one of these factors will be factored in, along with what our subjects experienced during our clinical trial. So nothing here is necessarily a gate, and all of it will be factored in throughout the NDA process for approval.
William Wood
analystThanks a lot. I’m grateful that you’re taking questions.
Jennifer Good
executiveThanks, William.
Brandon Folkes
analystHello. I appreciate you taking my questions, and congratulations on the updates. Perhaps just a single one from me. Is there any news regarding when the TIDAL respiratory physiology study will happen? At what point should we start paying closer attention to it? And perhaps the second portion of that, now that Jim has joined — welcome, Jim, it's wonderful to have you with us. But is it still your plan to conduct that trial? Could this be something that's being reviewed? Any detail at all about the commitment and the schedule for the TIDAL study would be terrific. Thank you.
Jennifer Good
executiveYes, I'll address the first 2, and then I'll have Jim respond. I don't believe his perspective differs. So, Brandon, as you're aware, the reason we're doing this trial is simply so we can establish who our Phase 3 patient population is, specifically in IPF. There's a subset of patients with sleep disordered breathing whom we set apart in our 2 earlier clinical trials, since we wanted to resolve certain issues regarding that; so we are — that trial is enrolling, it's screening patients and enrolling them. As for timing, we require that data before we reach our end of Phase 2 meeting on IPF, which, on the present schedule, will occur at some point in the second half of next year. I believe it's unblinded. I don't expect that; we likely won't release much data until we reach the conclusion and can actually interpret all the results and sort of determine what it means for our inclusion exclusion; but Jim, I'll let you provide any detail. I don't believe your perspective differs.
James Cassella
executiveNot at all — our thinking hasn't changed on that. For us, this is a solid, educational piece of research that will simply assist us in reaching a few choices down the road.
Brandon Folkes
analystMuch appreciated, and that news is wonderful to receive. Thanks for allowing me to ask.
Jennifer Good
executiveCertainly, I appreciate it. Brandon.
Ryan Deschner
analystHello. I'd like to know more about when the DEA might reach a decision on this — roughly, after the HAP results are available to you, what their ruling would be, or at least any comments they give regarding the possibility of scheduling. I'm also wondering at what dose level butorphanol is being given compared with the comparator. Thanks.
Jennifer Good
executiveSure, I can take both of those. Sadly, the DEA step arrives at the very end, assuming it arrives at all. Here's how it works: you file your NDA. FDA reviews the whole thing, consulting with CSS <<inaudible>>. In some cases it isn't even sent over to the DEA. They take everything into account. They examine the data you handed in, and it may never reach the DEA at all. When it does, it's included within the NDA review, and then scheduling happens alongside your approval; so it lands roughly just after that. Regarding the dose we're administering for butorphanol, it's an infusion of 6 milligrams given across 1 hour. A full study was run to essentially replicate the marketed inhaled form of butorphanol; we weren't able to use that one since it genuinely carried a taste. That made blinding extremely difficult; as a result, we wound up essentially replicating its PK using the 6 milligram infusion. All of that, though, was cleared with the FDA as the correct dose.
Ryan Deschner
analystUnderstood. Thanks a lot.
Jennifer Good
executiveYou're welcome. Thanks.
Jennifer Good
executiveThanks. We're eager to walk everyone through what comes out of the different clinical trials we've been running, and we'll do that soon. We appreciate you being here on today's call, and once it wraps up, we'll be around to address whatever follow-up questions come your way.
Operator
operatorThat brings us to the end of this conference call. We appreciate you joining today's presentation. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.